References
- Ames B. N., Durston W. E., Yamasaki E., Lee F. D. Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl. Acad. Sci. U. S. A. 1973; 70: 2281–2285, [PUBMED], [INFOTRIEVE]
- Ames B. N., Gold L. S., Willett W. C. The causes and prevention of cancer. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 5258–5265, [PUBMED], [INFOTRIEVE], [CSA]
- Bock K. W., Fröhling W., Remmer H. Influence of fasting and hemin on microsomal cytochromes and enzymes. Biochem. Pharmacol. 1973; 22: 1557–1564, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bolt H. M., Kappus H., Remmer H. Studies on the metabolism of ethynylestradiol in vitro and in vivo: the significance of 2‐hydroxylation and the formation of polar products. Xenobiotica 1973; 3: 773–785, [PUBMED], [INFOTRIEVE]
- Borghoff S. J., Short B. G., Swenberg J. A. Biochemical mechanisms and pathobiology of α2u‐globulin nephropathy. Annu. Rev. Pharmacol. Toxicol. 1990; 30: 349–367, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Borzelleca J. F. The art, the science, and the seduction of toxicology: an evolutionary development. Principles and Methods of Toxicology4th Ed., A. W. Hayes. Taylor & Francis, Philadelphia 2001; 1–21
- Brusick D. Genetic toxicology. Principles and Methods of Toxicology3rd ed., A. W. Hayes. Raven Press, New York 1994; 545–577
- Burchiel S. W., Knall C. M., Davis J. W., II, Paules R. S., Boggs S. E., Afshari C. A. Analysis of genetic and epigenetic mechanisms of toxicity: potential roles of toxicogenomics and proteomics in toxicology. Toxicol. Sci. 2001; 59: 193–195, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Calabrese E. J., Baldwin L. A. The frequency of U‐shaped dose responses in the toxicological literature. Toxicol. Sci. 2001; 62: 330–338, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Calabrese E. J., Baldwin L. A. The hormetic dose‐response model is more common than the threshold model in toxicology. Toxicol. Sci. 2003; 71: 246–250, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Carson R. Silent Spring. Houghton Mifflin, Boston 1962
- Cattley R. C., DeLuca J., Elcombe C., Fenner‐Crisp P., Lake B. G., Marsman D. S., Pastoor T. A., Popp J. A., Robinson D. E., Schwetz B., Tugwood J., Wahli W. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?. Regul. Toxicol. Pharmacol. 1998; 27: 47–60, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cherkaoui‐Malki M., Meyer K., Cao W. Q., Latruffe N., Yeldandi A. V., Rao M. S., Bradfield C. A., Reddy J. K. Identification of novel peroxisome proliferator‐activated receptor alpha (PPARα) target genes in mouse liver using cDNA microarray analysis. Gene Exp. 2001; 9: 291–304, [CSA]
- Cohen S. M., Ellwein L. B. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res. 1991; 51: 6493–6505, [PUBMED], [INFOTRIEVE]
- Cook J. W., Hewett C. L., Hieger I. The isolation of a cancer‐producing hydrocarbon from coal tar. Parts I, II, and III. J. Chem. 1933; 394–405
- DeRisi J. L., Iyer V. R., Brown P. O. Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 1997; 278: 680–686, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Doll R., Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst. 1981; 66: 1191–1308, [PUBMED], [INFOTRIEVE]
- Estabrook R. W. A tribute to James Robert Gillette. Drug Metab. Rev. 2003; 31: 1459–1460
- Evans D. C., Watt A. P., Nicoll‐Griffith D. A., Baillie T. A. Drug‐protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 2004; 17: 3–16, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gallo M. A. History and scope of toxicology. Casarett and Doull's Toxicology: The Basic Science of Poisons, C. D. Klaassen. McGraw‐Hill, New York 2001; 3–10
- Garrison P. M., Tullis K., Aarts J. M., Brouwer A., Giesy J. P., Denison M. S. Species‐specific recombinant cell lines as bioassay systems for the detection of 2,3,7,8‐tetrachlorodibenzo‐p‐dioxin‐like chemicals. Fundam. Appl. Toxicol. 1996; 30: 194–203, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gillette J. R. Kinetics of decomposition of chemically unstable metabolites in the presence of nucleophiles: derivation of equations used in graphical analyses. Pharmacology 1980; 20: 64–86, [PUBMED], [INFOTRIEVE]
- Gold L. S., Slone T. H., Ames B. N. What do animal cancer tests tell us about human cancer risk?: overview of analyses of the carcinogenic potency database. Drug Metab. Rev. 1998; 30: 359–404, [PUBMED], [INFOTRIEVE], [CSA]
- Greim H. Laudatio to Herbert Remmer. Arch. Toxciol. 1987; 60: 1–4, [CSA], [CROSSREF]
- Greim H., Schenkman J. B., Klotzbucher M., Remmer H. The influence of phenobarbital on the turnover of hepatic microsomal cytochrome b5 and cytochrome P450 hemes in the rat. Biochim. Biophys. Acta. 1970; 201: 20–25, [PUBMED], [INFOTRIEVE]
- Guengerich F. P. Introduction and historical perspective. Biotransformation, Vol. 3, Comprehensive Toxicology, Chap. 1, F. P. Guengerich. Elsevier, Oxford 1997; 1–6
- Guengerich F. P. The Vanderbilt University Center in Molecular Toxicology: the first thirty years. Drug Metab. Rev. 1999; 31: 1–11, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hamadeh H. K., Bushel P. R., Jayadev S., DiSorbo O., Bennett L., Li L., Tennant R., Stoll R., Barrett J. C., Paules R. S., Blanchard K., Afshari C. A. Prediction of compound signature using high density gene expression profiling. Toxicol. Sci. 2002; 67: 232–240, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hengstler J. G., Bogdanffy M. S., Bolt H. M., Oesch F. Challenging dogma: thresholds for genotoxic carcinogens? The case of vinyl acetate. Annu. Rev. Pharmacol. Toxicol. 2003; 43: 485–520, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hildebrandt A., Remmer H., Estabrook R. W. Cytochrome P450 of liver microsomes: one pigment or many. Biochem. Biophys. Res. Commun. 1968; 30: 607–612, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ioannides C. Dennis Vernon William Parke, Ph.D., D.Sc., C.Chem., F.R.S.C, F.I.Biol., F.R.C.Path. (November 1922–November 2002)—in memoriam. Drug Metab. Rev. 2003; 5–6
- Jollow D. J., Mitchell J. R., Potter W. Z., Davis D. C., Gillette J. R., Brodie B. B. Acetaminophen‐induced hepatic necrosis. II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther. 1973; 187: 195–202, [PUBMED], [INFOTRIEVE]
- Kappus H., Bolt H. M., Remmer H. Irreversible protein binding of metabolites of ethynylestradiol in vivo and in vitro. Steroids 1973; 22: 203–225, [PUBMED], [INFOTRIEVE], [CROSSREF]
- LeBeau J. Perry J. Gehring DVM, PhD (March 15, 1936–November 6, 2003). Toxicol. Sci. 2004; 77: 1–2, [CROSSREF]
- Liebler D. C. Introduction to Proteomics. Tools for the New Biology. Humana Press, Totowa, NJ 2002
- Lindon J. C., Holmes E., Nicholson J. K. So what's the deal with metabonomics?. Anal. Chem. 2003; 75: 384A–391A, [PUBMED], [INFOTRIEVE]
- Miller J. A. Carcinogenesis by chemicals: an overview. G.H.A. Clowes Memorial Lecture. Cancer Res. 1970; 30: 559–576, [PUBMED], [INFOTRIEVE]
- Miller J. A. Research in chemical carcinogenesis with Elizabeth Miller—a trail of discovery with our associates. Drug Metab. Rev. 1994; 26: 1–36, [PUBMED], [INFOTRIEVE], [CSA]
- Miller H., Conko G. The precautionary principle. Nat. Biotechnol. 2000; 18: 697, [CSA]
- Nebert D. W., Jorge–Nebert L., Vesell E. S. Pharmacogenomics and “Individualized Drug Therapy:” high expectations and disappointing achievements. Am. J. Pharmacogenomics 2003; 3: 361–370, [PUBMED], [INFOTRIEVE], [CSA]
- Nicholson J. K., Wilson I. D. Understanding ‘global’ systems biology: metabonomics and the continuum of metabolism. Nature 2003; 2: 668–676
- Noort D., Fidder A., Hulst A. G. Modification of human serum albumin by acrylamide at cysteine‐34: a basis for a rapid biomonitoring procedure. Arch. Toxicol. 2003; 77: 543–545, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nuwaysir E. F., Bittner M., Trent J., Barrett J. C., Afshari C. A. Microarrays and toxicology: the advent of toxicogenomics. Mol. Carcinog. 1999; 24: 153–159, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Parke D. V., Williams R. T. Detoxication. XXX. Metabolism of benzene. (a) Determination of benzene. (b) Elimination of unchanged benzene by rabbits. Biochem. J. 1950; 46: 236–243
- Qiu Y., Benet L. Z., Burlingame A. L. Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two‐dimensional gel electrophoresis and mass spectrometry. J. Biol. Chem. 1998; 273: 17940–17953, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rehn L. Über Blasentumoren bei Fuchsinarbeitern. Arch. Clin. Chirgurie 1895; 50: 588–600
- Remmer H. The acceleration of evipan oxidation and the demethylation of methylaminopyrine by barbiturates. Naunyn‐Schmiedeberg's Arch. Exp. Pathol. Pharmakol. 1957; 237: 296–307
- Roberts S. A., Price V. F., Jollow D. J. Acetaminophen structure‐toxicity studies: in vivo covalent binding of a nonhepatotoxic analog, 3‐hydroxyacetanilide. Toxicol. Appl. Pharmacol. 1990; 105: 195–208, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Stott W. T., Bus J. S., Gibson J. E., Gehring P. J. Role of mechanistic data in the interpretation of oncogenicity data and risk assessment. J. Environ. Sci. Health 1991; C8: 287–298
- Swenberg J. A. Risk assessment of chemicals causing α2u‐globulin nephropathy. Regul. Toxicol. Pharmacol. 1991; 13: 1–2, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Thomas R. S., Rank D. R., Penn S. G., Zastrow G. M., Hayes K. R., Pande K., Glover E., Silander T., Craven M. W., Reddy J. K., Jovanovich S. B., Bradfield C. A. Identification of toxicologically predictive gene sets using cDNA microarrays. Molec. Pharmacol. 2001; 60: 1189–1194, [CSA]
- Thomas R. S., Rank D. R., Penn S. G., Craven M. W., Drinkwater N. R., Bradfield C. A. Developing toxicologically predictive gene sets using cDNA microarrays and Bayesian classification. Methods Enzymol. 2002; 357: 198–205, [PUBMED], [INFOTRIEVE]
- Yamagiwa K., Ichikawa K. Experimentelle Studie über die Pathogenese der Epithelialgeschwulste. Mitt. Med. Fak. Tokio 1915; 15: 295–344